As announced in November 2019, the Acquisition secures a complementary portfolio of leading protein conjugation technologies and products for Abcam, including well-known industry brands Lightning-Link® and CaptSureTM.
Commenting on the completion of the Acquisition, Alan Hirzel, CEO of Abcam, said: “We are delighted to have completed this transaction and welcome our new colleagues to Abcam. Expedeon’s portfolio of products and technology, combined with Abcam’s antibody and protein strengths, place us well to address the growing need for antibody conjugation and multiplexing solutions.”
Ondra LLP provided advice to the Board of Directors of Abcam in relation to this transaction.